狼疮性肾炎中膜攻击复合物(MAC)沉积与高血压及治疗临床应答不佳相关
研究对30例符合4项ACR或SLICC标准的SLE患者肾活检组织行免疫组化检测补体C9以反映膜攻击复合物沉积,13/30(43.3%)肾小球C9染色阳性;C9阳性患者血压显著更高、男性更多、C3有降低趋势,6个月时C9阳性者无应答比例45.5% vs C9阴性者13.3%,多因素校正后C9阳性者仍更可能无应答。作者认为MAC沉积可能是疾病更重和治疗应答不佳的生物标志物。
要点
- 30例狼疮性肾炎肾活检中13/30(43.3%)肾小球C9染色阳性,提示MAC沉积。
- C9阳性者血压显著更高、男性更多、C3有降低趋势,ISN/RPN分型及活动/慢性指数无显著差异。
- 6个月无应答:C9阳性5/11(45.5%)vs C9阴性2/15(13.3%),OR=5.4(95%CI 0.8, 36.4)。
核心结论
- 本研究提示以C9染色测定的MAC沉积可能是狼疮性肾炎疾病更重和治疗应答不佳的生物标志物。
- MAC染色可能有助于狼疮肾活检的常规检查,并识别具有侵袭性疾病风险、可能适合靶向终末补体通路新疗法的患者。
研究设计与样本
- 对30例符合4项ACR或SLICC标准的SLE患者肾活检组织,使用未标记鼠抗人补体C9行免疫组化检测。
- 在活检时、6个月和12个月评估临床参数。
主要发现
- 30例肾活检病理分型为II型2例、III型5例、IV型8例、V型5例、III+V型8例、IV+V型2例。
- 13/30(43.3%)活检肾小球C9染色阳性。
- C9阳性患者血压显著更高,C3有降低趋势,男性更多。
- C9阳性与阴性组间ISN/RPN分型、活动指数或慢性指数无显著差异。
- 6个月无应答:C9阳性5/11(45.5%)vs C9阴性2/15(13.3%);C9阳性者更可能无应答,OR=5.4(95%CI 0.8, 36.4)。
临床怎么用
- 作者认为MAC染色可能有助于狼疮肾活检的常规检查,并识别具有侵袭性疾病风险、可能适合靶向终末补体通路新疗法的患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To study membrane attack complex in lupus nephritis as a potential biomarker for disease intensity and prognostic indicator for response to treatment. METHODS: Immunohistochemistry was performed using unconjugated, murine anti-human complement C9 on kidney biopsies from 30 SLE patients who fulfilled 4 ACR or SLICC criteria. Clinical parameters were assessed at time of biopsy, 6 and 12 months. RESULTS: 30 renal biopsies were obtained from patients with Class II (2), III (5), IV (8), V (5), III+V (8) and IV+V (2). 13/30 (43.3%) biopsies stained positive for glomerular C9. Patients with positive C9 had significantly higher blood pressure, trend towards lower C3, and male gender. There was no significant difference for ISN/RPN class, activity or chronicity indices between C9 positive and negative groups. 5/11 (45.5%) patients positive for C9 did not respond to therapy at 6 months compared with 2/15 (13.3%) patients negative for C9. C9 positive patients were more likely to be a non-responder at 6 months (OR = 5.4, 95% CI: 0.8, 36.4) compared to C9 negative patients. After adjusting for systolic blood pressure, compliance to treatment and proteinuria in a multivariate logistic model, C9 positive patients remained more likely to be non-responders (OR = 4.6, 95% CI: 0.3, 70.9). CONCLUSION: This study suggests that MAC deposition measured as C9 staining may be a biomarker for more intense disease and poor response to treatment in lupus nephritis. MAC staining may be useful in routine studies of lupus biopsies and identify patients at risk for aggressive disease who may be candidates for novel therapies targeting terminal complement pathway.
引用
- Wang S, Wu M, Chiriboga L, et al. Membrane attack complex (mac) deposition in lupus nephritis is associated with hypertension and poor clinical response to treatment. Semin Arthritis Rheum. 2018. PMID: 29395256. doi:10.1016/j.semarthrit.2018.01.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。